Newly Diagnosed Multiple Myeloma
Conditions
Interventions
None listed
Sponsors
Janssen Pharmaceutical K.K.
INTAGE Healthcare Inc., Plamed Inc.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.18+ years of age at the time of the study participation. 2.Board certified in oncology or hematology and currently practicing medicine in Japan. 3.Has prescribed and managed at least one TIE NDMM patient in a real-world setting, with clinical experience of either: a) A Daratumumab SC-based regimen (e.g., DRd, DVRd), OR b) An intravenous (IV) anti-CD38 antibody-based regimen (e.g., IsaVRd) (Note: Recruitment will prioritize respondents with experience in both regimen types.) 4.Japanese-language proficient. 5.Provides verbal consent to all terms of research participation. 6.Willing and able to participate in a recorded web-based video conferencing interview.
Exclusion criteria
Exclusion criteria: Any individual who does not meet all inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| As this study is qualitative in nature, typical outcome measures will not be collected for quantitative analysis. Key themes will include: 1) Impact on clinic Time and Motion of Daratumumab SC-based regimens (including comparison to other IV regimens) 2) Perceived Staff Burden and Preference related to Daratumumab SC-based regimens 3) HCPs' perspective on Patient Experience and Preference, focusing on aspects that reduce treatment burden 4) Physicians' perspectives on the future therapeutic landscape and positioning of Daratumumab SC-based regimens | — |
Countries
Japan
Contacts
Public ContactTetsuri Suzuki
INTAGE Healthcare Inc. Value & Access Department
Outcome results
None listed